{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:41:32Z","timestamp":1794606092422,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The objective of this network meta-analysis was to evaluate and compare the efficacy and safety of different antimicrobial regimens used in the treatment of pneumonia caused by extensively drug-resistant (XDR) or multidrug-resistant (MDR)\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (AB). Given the increasing prevalence of resistant strains, identifying optimal treatment strategies is crucial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We systematically analyzed data from randomized controlled trials and retrospective cohort studies retrieved from major electronic databases. The included studies evaluated all-cause mortality, clinical success, microbiological eradication, and nephrotoxicity associated with cefiderocol, intravenous (IV) colistin, inhaled colistin, igecycline, sulbactam, and their combination-based regimens in patients with MDR\/XDR-AB pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 19 eligible studies involving 1,941 participants were included in the analysis. Cefiderocol-containing regimens demonstrated the greatest reduction in all-cause mortality (odds ratio (OR): 0.24; 95% CI: 0.09\u20130.68) compared to other therapies. In terms of clinical success, cefiderocol-containing regimens (OR: 2.77; 95% CI: 1.07\u20137.19) and inhaled colistin (OR: 2.61; 95% CI: 1.14\u20135.99) were significantly more effective than other regimens. Microbiological eradication was most notable with inhaled colistin, and with IV colistin combined with sulbactam or tigecycline. However, nephrotoxicity was commonly observed with IV colistin, while tigecycline monotherapy showed the lowest nephrotoxicity risk (OR: 0.15; 95% CI: 0.04\u20130.60).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides comprehensive evidence on current and emerging treatments for MDR\/XDR-AB pneumonia. Cefiderocol-containing regimens appears to be the most effective regimen in reducing mortality and improving clinical outcomes, though nephrotoxicity risks must be carefully considered when using IV colistin-based therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12640-z","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:23:14Z","timestamp":1768904594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies"],"prefix":"10.1186","volume":"26","author":[{"given":"Ming-Ying","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"12640_CR1","doi-asserted-by":"publisher","first-page":"11367","DOI":"10.1016\/j.isci.2024.111367","volume":"27","author":"A Thacharodi","year":"2024","unstructured":"Thacharodi A, Vithlani A, Hassan S, et al. Carbapenem-resistant acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience. 2024;27:11367.","journal-title":"iScience"},{"key":"12640_CR2","doi-asserted-by":"publisher","first-page":"793615","DOI":"10.3389\/fmed.2022.793615","volume":"9","author":"S Roy","year":"2022","unstructured":"Roy S, Chowdhury G, Mukhopadhyay AK, et al. Convergence of biofilm formation and antibiotic resistance in acinetobacter baumannii infection. Front Med (Lausanne). 2022;9:793615.","journal-title":"Front Med (Lausanne)"},{"key":"12640_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/533452","volume":"197","author":"LB Rice","year":"2008","unstructured":"Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079\u201381.","journal-title":"J Infect Dis"},{"key":"12640_CR4","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/ijms25136814","volume":"25","author":"A Marino","year":"2024","unstructured":"Marino A, Augello E, Stracquadanio S, et al. Unveiling the secrets of acinetobacter baumannii: Resistance, current Treatments, and future innovations. Int J Mol Sci. 2024;25:6814.","journal-title":"Int J Mol Sci"},{"key":"12640_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","volume":"21","author":"AY Peleg","year":"2008","unstructured":"Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538\u201382.","journal-title":"Clin Microbiol Rev"},{"key":"12640_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","volume":"78","author":"M Wang","year":"2024","unstructured":"Wang M, Ge L, Chen L, et al. Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter baumannii among patients from different global regions. Clin Infect Dis. 2024;78:248\u201358.","journal-title":"Clin Infect Dis"},{"key":"12640_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403. Epub ahead of print.","journal-title":"Clin Infect Dis"},{"key":"12640_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28:521\u201347.","journal-title":"Clin Microbiol Infect"},{"key":"12640_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics13030261","volume":"13","author":"P Rafailidis","year":"2024","unstructured":"Rafailidis P, Panagopoulos P, Koutserimpas C, et al. Current therapeutic approaches for Multidrug-Resistant and extensively Drug-Resistant Acinetobacter baumannii infections. Antibiot (Basel). 2024;13:261.","journal-title":"Antibiot (Basel)"},{"key":"12640_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/antibiotics10111344","volume":"10","author":"S Karakonstantis","year":"2021","unstructured":"Karakonstantis S, Ioannou P, Samonis G, et al. Systematic review of antimicrobial combination options for Pandrug-Resistant Acinetobacter baumannii. Antibiot (Basel). 2021;10:1344.","journal-title":"Antibiot (Basel)"},{"key":"12640_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10096-024-04831-w","volume":"43","author":"A Uskudar-Guclu","year":"2024","unstructured":"Uskudar-Guclu A, Danyildiz S, Mirza HC, et al. In vitro activity of Cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various \u03b2-lactamase encoding genes. Eur J Clin Microbiol Infect Dis. 2024;43:1171\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"12640_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/antibiotics10060649","volume":"10","author":"C K\u00f6nig","year":"2021","unstructured":"K\u00f6nig C, Both A, Rohde H, et al. Cefiderocol in critically ill patients with Multi-Drug resistant pathogens: Real-Life data on pharmacokinetics and Microbiological surveillance. Antibiot (Basel). 2021;10:649.","journal-title":"Antibiot (Basel)"},{"key":"12640_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"12640_CR14","doi-asserted-by":"crossref","unstructured":"Ai MY, Chang WL. 2025. Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies. Available online: https:\/\/inplasy.com\/inplasy-2025-8-0032\/","DOI":"10.37766\/inplasy2025.8.0032"},{"key":"12640_CR15","doi-asserted-by":"publisher","first-page":"e0165889","DOI":"10.1371\/journal.pone.0165889","volume":"11","author":"J Zhang","year":"2016","unstructured":"Zhang J, Yuan Y, Chu H. The impact of excluding trials from network meta-analyses\u2013an empirical study. PLoS ONE. 2016;11:e0165889.","journal-title":"PLoS ONE"},{"key":"12640_CR16","doi-asserted-by":"publisher","first-page":"e2016014","DOI":"10.4178\/epih.e2016014","volume":"38","author":"JM Bae","year":"2016","unstructured":"Bae JM. A suggestion for quality assessment in systematic reviews of observational studies in nutritional epidemiology. Epidemiol Health. 2016;38:e2016014.","journal-title":"Epidemiol Health"},{"key":"12640_CR17","first-page":"285","volume-title":"Cochrane handbook for systematic reviews of Interventions, version 6.4","author":"A Chaimani","year":"2023","unstructured":"Chaimani A, Caldwell DM, Li T, et al. Cochrane handbook for systematic reviews of Interventions, version 6.4. Chichester: John Wiley and Sons Ltd; 2023. pp. 285\u2013320."},{"key":"12640_CR18","first-page":"143","volume-title":"Cochrane handbook for systematic reviews of Interventions, version 6.4","author":"JP Higgins","year":"2023","unstructured":"Higgins JP, Li T, Deeks JJ. Cochrane handbook for systematic reviews of Interventions, version 6.4. Chichester: John Wiley and Sons Ltd; 2023. pp. 143\u201376."},{"key":"12640_CR19","first-page":"241","volume-title":"Cochrane handbook for systematic reviews of Interventions, version 6.4","author":"JJ Deeks","year":"2023","unstructured":"Deeks JJ, Higgins JP, Altman DG. Cochrane handbook for systematic reviews of Interventions, version 6.4. Chichester: John Wiley and Sons Ltd; 2023. pp. 241\u201384."},{"key":"12640_CR20","first-page":"349","volume-title":"Cochrane handbook for systematic reviews of Interventions, version 6.4","author":"MJ Page","year":"2023","unstructured":"Page MJ, Higgins JP, Sterne JA. Cochrane handbook for systematic reviews of Interventions, version 6.4. Chichester: John Wiley and Sons Ltd; 2023. pp. 349\u201374."},{"key":"12640_CR21","first-page":"569","volume-title":"Cochrane handbook for systematic reviews of Interventions, version 6.4","author":"JPT Higgins","year":"2023","unstructured":"Higgins JPT, Eldridge S, Li T. Cochrane handbook for systematic reviews of Interventions, version 6.4. Chichester: John Wiley and Sons Ltd; 2023. pp. 569\u201393."},{"key":"12640_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","volume":"56","author":"AP Betrosian","year":"2008","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, et al. Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56:432\u20136.","journal-title":"J Infect"},{"key":"12640_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.","journal-title":"BMC Infect Dis"},{"key":"12640_CR24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/antibiotics12061048","volume":"12","author":"L Dalfino","year":"2023","unstructured":"Dalfino L, Stufano M, Bavaro DF, et al. Effectiveness of First-Line therapy with old and novel antibiotics in Ventilator-Associated pneumonia caused by Carbapenem-Resistant Acinetobacter baumannii: A real Life, Prospective, Observational, Single-Center study. Antibiot (Basel). 2023;12:1048.","journal-title":"Antibiot (Basel)"},{"key":"12640_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12879-022-07778-5","volume":"22","author":"Y Deng","year":"2022","unstructured":"Deng Y, Chen L, Yue M, et al. Sulbactam combined with Tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect Dis. 2022;22:795.","journal-title":"BMC Infect Dis"},{"key":"12640_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","volume":"57","author":"E Durante-Mangoni","year":"2013","unstructured":"Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349\u201358.","journal-title":"Clin Infect Dis"},{"key":"12640_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jmii.2014.08.009","volume":"49","author":"TC Hsieh","year":"2016","unstructured":"Hsieh TC, Chen FL, Ou TY, et al. Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization. J Microbiol Immunol Infect. 2016;49:523\u201330.","journal-title":"J Microbiol Immunol Infect"},{"key":"12640_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","volume":"42","author":"G Kalin","year":"2014","unstructured":"Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection. 2014;42:37\u201342.","journal-title":"Infection"},{"key":"12640_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijantimicag.2014.01.016","volume":"43","author":"T Khawcharoenporn","year":"2014","unstructured":"Khawcharoenporn T, Pruetpongpun N, Tiamsak P, et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents. 2014;43:378\u201382.","journal-title":"Int J Antimicrob Agents"},{"key":"12640_CR30","doi-asserted-by":"publisher","first-page":"e0150642","DOI":"10.1371\/journal.pone.0150642","volume":"11","author":"WY Kim","year":"2016","unstructured":"Kim WY, Moon JY, Huh JW, et al. Comparable efficacy of Tigecycline versus colistin therapy for Multidrug-Resistant and extensively Drug-Resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS ONE. 2016;11:e0150642.","journal-title":"PLoS ONE"},{"key":"12640_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1248\/bpb.b13-00109","volume":"37","author":"SH Kwon","year":"2014","unstructured":"Kwon SH, Ahn HL, Han OY, et al. Efficacy and safety profile comparison of colistin and Tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull. 2014;37:340\u20136.","journal-title":"Biol Pharm Bull"},{"key":"12640_CR32","doi-asserted-by":"publisher","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62:106825.","journal-title":"Int J Antimicrob Agents"},{"key":"12640_CR33","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.2147\/IDR.S225518","volume":"12","author":"C Ungthammakhun","year":"2019","unstructured":"Ungthammakhun C, Vasikasin V, Changpradub D. Clinical outcomes of colistin in combination with either 6-G sulbactam or carbapenems for the treatment of extensively Drug-Resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam, A prospective cohort study. Infect Drug Resist. 2019;12:2899\u2013904.","journal-title":"Infect Drug Resist"},{"key":"12640_CR34","doi-asserted-by":"publisher","first-page":"116481","DOI":"10.1016\/j.diagmicrobio.2024.116481","volume":"110","author":"LJKG Yee","year":"2024","unstructured":"Yee LJKG, Abad CLR, Cabaluna ITG, et al. Outcomes of adult patients with multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia treated with monotherapy versus combination therapy in a tertiary hospital. Diagn Microbiol Infect Dis. 2024;110:116481.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"12640_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3855\/jidc.6195","volume":"9","author":"GR Yilmaz","year":"2015","unstructured":"Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9:476\u201385.","journal-title":"J Infect Dev Ctries"},{"key":"12640_CR36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jmii.2019.08.007","volume":"53","author":"JY Zheng","year":"2020","unstructured":"Zheng JY, Huang SS, Huang SH, et al. Colistin for pneumonia involving multidrug-resistant acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect. 2020;53:854\u201365.","journal-title":"J Microbiol Immunol Infect"},{"key":"12640_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of Cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340.","journal-title":"Lancet Infect Dis"},{"key":"12640_CR38","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3:dlab174.","journal-title":"JAC Antimicrob Resist"},{"key":"12640_CR39","doi-asserted-by":"crossref","unstructured":"Falcone M, Tiseo G, Leonildi A et al. Cefiderocol- compared to Colistin-Based regimens for the treatment of severe infections caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022, 66, e0214221.","DOI":"10.1128\/aac.02142-21"},{"key":"12640_CR40","doi-asserted-by":"publisher","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","volume":"5","author":"E Rando","year":"2023","unstructured":"Rando E, Cutuli SL, Sangiorgi F, et al. Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist. 2023;5:dlad085.","journal-title":"JAC Antimicrob Resist"},{"key":"12640_CR41","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1017\/ice.2021.348","volume":"43","author":"AT Peters","year":"2022","unstructured":"Peters AT, Pickens CI, Postelnick MJ, et al. Decreasing incidence of Acinetobacter baumannii pneumonia and trends in antibiotic consumption: A single-center retrospective observational study. Infect Control Hosp Epidemiol. 2022;43:1155\u201361.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"12640_CR42","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","volume":"184","author":"DR Chung","year":"2011","unstructured":"Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409\u201317.","journal-title":"Am J Respir Crit Care Med"},{"key":"12640_CR43","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1128\/AAC.00985-12","volume":"57","author":"M Karvanen","year":"2013","unstructured":"Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;57:668\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"12640_CR44","doi-asserted-by":"publisher","first-page":"105889","DOI":"10.1016\/j.ijantimicag.2020.105889","volume":"55","author":"HT Chien","year":"2020","unstructured":"Chien HT, Lin YC, Sheu CC, et al. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;55:105889.","journal-title":"Int J Antimicrob Agents"},{"key":"12640_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333\u201341.","journal-title":"Clin Infect Dis"},{"key":"12640_CR46","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-16","volume":"61","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61:e02319\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"12640_CR47","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00134-012-2628-7","volume":"38","author":"ZE Athanassa","year":"2012","unstructured":"Athanassa ZE, Markantonis SL, Fousteri MZ, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38:1779\u201386.","journal-title":"Intensive Care Med"},{"key":"12640_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","volume":"10","author":"G De Pascale","year":"2020","unstructured":"De Pascale G, Lisi L, Ciotti GMP, et al. Pharmacokinetics of high-dose Tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020;10:94.","journal-title":"Ann Intensive Care"},{"key":"12640_CR49","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2147\/IDR.S322803","volume":"14","author":"H Han","year":"2021","unstructured":"Han H, Qin W, Zheng Y, et al. High-Dose versus Standard-Dose Tigecycline treatment of secondary bloodstream infections caused by extensively Drug-Resistant Acinetobacter baumannii: an observational cohort study. Infect Drug Resist. 2021;14:3837\u201348.","journal-title":"Infect Drug Resist"},{"key":"12640_CR50","doi-asserted-by":"publisher","first-page":"dlae203","DOI":"10.1093\/jacamr\/dlae203","volume":"6","author":"Y Abouelhassan","year":"2024","unstructured":"Abouelhassan Y, Kuti JL, Nicolau DP, et al. Pharmacokinetic\/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: Establishing in vivo efficacy targets in the epithelial lining fluid. JAC Antimicrob Resist. 2024;6:dlae203.","journal-title":"JAC Antimicrob Resist"},{"key":"12640_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3947\/ic.2024.0055","volume":"56","author":"SJ Choi","year":"2024","unstructured":"Choi SJ, Kim ES. Optimizing treatment for Carbapenem-Resistant Acinetobacter baumannii complex infections: A review of current evidence. Infect Chemother. 2024;56:171\u201387.","journal-title":"Infect Chemother"},{"key":"12640_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13643-024-02695-x","volume":"13","author":"C Lai","year":"2024","unstructured":"Lai C, Ma Z, Zhang J, et al. Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis. Syst Rev. 2024;13:309.","journal-title":"Syst Rev"},{"key":"12640_CR53","doi-asserted-by":"publisher","first-page":"772372","DOI":"10.3389\/fmed.2022.772372","volume":"9","author":"K Chang","year":"2022","unstructured":"Chang K, Wang H, Zhao J, et al. Polymyxin B\/Tigecycline combination vs. Polymyxin B or Tigecycline alone for the treatment of Hospital-Acquired pneumonia caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii. Front Med (Lausanne). 2022;9:772372.","journal-title":"Front Med (Lausanne)"},{"key":"12640_CR54","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s15010-024-02307-9","volume":"52","author":"J Yu","year":"2024","unstructured":"Yu J, Zhang B, Yang Y, et al. A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections. Infection. 2024;52:2445\u201354.","journal-title":"Infection"},{"key":"12640_CR55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40121-023-00776-3","volume":"12","author":"\u00c1M Fendian","year":"2023","unstructured":"Fendian \u00c1M, Albanell-Fern\u00e1ndez M, Tuset M, et al. Real-Life data on the effectiveness and safety of Cefiderocol in severely infected patients: A case series. Infect Dis Ther. 2023;12:1205\u201316.","journal-title":"Infect Dis Ther"},{"key":"12640_CR56","doi-asserted-by":"publisher","first-page":"e0029024","DOI":"10.1128\/aac.00290-24","volume":"68","author":"E Huang","year":"2024","unstructured":"Huang E, Thompson RN, Moon SH, et al. Treatment-emergent Cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor PirA. Antimicrob Agents Chemother. 2024;68:e0029024.","journal-title":"Antimicrob Agents Chemother"},{"key":"12640_CR57","doi-asserted-by":"publisher","first-page":"107047","DOI":"10.1016\/j.ijantimicag.2023.107047","volume":"63","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cosentino F, Giannella M, et al. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis. Int J Antimicrob Agents. 2024;63:107047.","journal-title":"Int J Antimicrob Agents"},{"key":"12640_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1186\/s12879-024-09979-6","volume":"24","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Mao W, Zhao C, et al. Correction: Comparison of Cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis. BMC Infect Dis. 2024;24:1086.","journal-title":"BMC Infect Dis"},{"key":"12640_CR59","doi-asserted-by":"publisher","first-page":"e01221","DOI":"10.1128\/AAC.01221-20","volume":"64","author":"S Malik","year":"2020","unstructured":"Malik S, Kaminski M, Landman D, et al. Cefiderocol resistance in Acinetobacter baumannii: roles of \u03b2-Lactamases, siderophore Receptors, and penicillin binding protein 3. Antimicrob Agents Chemother. 2020;64:e01221\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"12640_CR60","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23:1072\u201384.","journal-title":"Lancet Infect Dis"},{"key":"12640_CR61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40261-021-01010-z","volume":"41","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Amikacin liposome inhalation suspension in refractory Mycobacterium avium complex lung disease: A profile of its use. Clin Drug Investig. 2021;41:405\u201312.","journal-title":"Clin Drug Investig"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12640-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:02:25Z","timestamp":1770987745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12640-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12640"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12640-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}